Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119855 | 0.84 | MEN1 (0.43) | HPGDKDM4EKMT2AMEN1TP53 | |
| SCHEMBL2117885 | 0.82 | ALDH1A1 (0.37) | HPGDKDM4EKMT2AMEN1TP53 | |
| SCHEMBL2118117 | 0.81 | SLC22A12 (0.36) | KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2117206 | 0.80 | SYK (0.46) | KDM4ETP53ALDH1A1MAPTHSD17B10 | |
| SCHEMBL2120158 | 0.78 | TP53 (0.40) | KMT2AMEN1TP53PKMMAPT | |
| SCHEMBL2119820 | 0.77 | MAPT (0.38) | HPGDKDM4EKMT2AMEN1TP53 | |
| SCHEMBL2118304 | 0.75 | SGK1 (0.36) | MAPTLMNA | |
| SCHEMBL2119291 | 0.75 | KMT2A (0.35) | KMT2AMEN1TP53ALDH1A1PKM | |
| SCHEMBL2116556 | 0.75 | SGK1 (0.38) | — | |
| SCHEMBL2119384 | 0.75 | MAPT (0.36) | HPGDKDM4ETP53ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | HPGD 1027/4885KDM4E 191/4885TSHR 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.